Alokendra Ghosh and the Radhakrishnan group have developed A multi-scale model to predict responses to different cancer treatments
Abstract:
Clinical Cancer models need to incorporate a wide variety of patient data and tumor heterogeneity which requires integration of multiple models. Due to differences in time and length scales of individual processes, such a model integration is a challenging task. Here we have developed an integrated framework combining ErbB receptor mediated Ras-MAPK and PI3K/AKT pathway with p53 mediated DNA damage response pathway. We have applied this in a clinical setting to predict patient specific response of different treatments in cancers of prostate, lung and kidney.”